What is the Fiscal Year for Aptevo Therapeutics?
Date: November 13, 2026
Aptevo Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Seattle, WA
Industry
Biotechnology Research
Stock Symbol
APVO
Description
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST. At Aptevo Therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning Aptevo Therapeutics to develop the science of what’s next in biotechnology.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Aptevo Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.